Patents by Inventor Dauphine S. Barone

Dauphine S. Barone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING AUTOIMMUNE AND CHRONIC INFLAMMATORY CONDITIONS USING ANTAGONISTS OF CD30 OR CD30L
    Publication number: 20100071079
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Application
    Filed: November 10, 2009
    Publication date: March 18, 2010
    Applicant: Immunex Corporation
    Inventors: Kendall M. MOHLER, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30L
    Publication number: 20080213259
    Abstract: The invention provides methods of treating autoimmnune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Application
    Filed: August 16, 2007
    Publication date: September 4, 2008
    Applicant: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 7273609
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 7122183
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF? inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF? inhibitors.
    Type: Grant
    Filed: August 26, 2003
    Date of Patent: October 17, 2006
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Publication number: 20040076626
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Application
    Filed: August 26, 2003
    Publication date: April 22, 2004
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Patent number: 6652854
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: November 25, 2003
    Assignee: Immunex Corporation
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Mary K. Kennedy
  • Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    Publication number: 20020064527
    Abstract: The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNF&agr; inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNF&agr; inhibitors.
    Type: Application
    Filed: August 3, 2001
    Publication date: May 30, 2002
    Inventors: Kendall M. Mohler, Dauphine S. Barone, Jacques J. Peschon, Mary K. Kennedy, John D. Pluenneke